Nuvectis Pharma Inc.

NVCT
$18.70 (- $0.50 - 2.60%)
Last updated: 2026-07-08 14:29 UTC
NVCT Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS67080T1088
CUSIP67080T108
Market Price18.7
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.38
Market Cap$197.5M
Book Value0.94
Price to Book8.237
Beta0.73
52w High29.28
52w Low5.55
Next Earnings DateN/A

Nuvectis Pharma Inc. trades under ticker NVCT on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US67080T1088, CUSIP 67080T108.

About the Company
Nuvectis Pharma Inc. is a biopharmaceutical company engaged in the development and commercialization of innovative cancer treatments. Its primary function is to explore novel therapies that address significant unmet medical needs in oncology. The company focuses on advancing proprietary compounds through clinical trials, aiming to transform the therapeutic landscape for cancer patients. Nuvectis is deeply involved in pioneering research, leveraging cutting-edge technology and strategic collaborations with research institutions. Its work impacts sectors within healthcare and pharmaceuticals, particularly those devoted to oncology and biopharmaceutical innovation. By contributing to the pipeline of potential cancer therapies, Nuvectis Pharma Inc. plays a crucial role in the drug development process, attracting interest from both scientific communities and investors seeking advancements in health-related technologies. Its efforts highlight the importance of supportive frameworks for novel drug development and underscore the complex landscape of modern oncology treatment research.
Price History